About Jasper Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://jaspertx.com/
Frequently Asked Questions
What is the 52-week range for JSPR?
The 52-week high is $2.69 and the 52-week low is $0.3151.
What is the P/E ratio for JSPR?
The P/E ratio data is currently unavailable.
What is the dividend yield for JSPR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -618.87%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 12.34.
Analyst Recommendation Trends
Wall Street analyst consensus for JSPR over the last few months:
Latest JSPR News
Jasper Therapeutics Appoints Jeet Mahal As Interim Principal Financial Officer Effective October 9, 2026; Herb Cross Resigns As CFO Effective October 9, 2026
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date/Time: Wednesda
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-31 | Shizuru Judith Anne | +7,500 | - | - |
| 2026-07-31 | Lucas Svetlana | +7,500 | - | - |
| 2026-07-31 | Crutcher Patrick J | +7,500 | - | - |
| 2026-07-31 | EMSTER KURT VON | +7,500 | - | - |
| 2026-07-31 | WIGGANS THOMAS G | +7,500 | - | - |
| 2026-07-20 | Ros Matthew E | +881 | - | - |
| 2026-07-20 | Crutcher Patrick J | +888 | - | - |
| 2026-07-16 | Crutcher Patrick J | +15,000 | - | - |
| 2026-02-06 | Mahal Jeetinder Singh | +500,000 | - | - |
| 2026-01-02 | Mahal Jeetinder Singh | +90,000 | - | - |
| 2026-01-02 | CROSS HERB | +90,000 | - | - |
| 2026-01-02 | MARTELL RON | +234,000 | - | - |